MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models

Anti-Cancer Drugs

Volumn 24, Issue 10, 2013, Pages 1030-1038

  Gu, Juan J ^a   Hernandez Ilizaliturri, Francisco J ^a   Mavis, Cory ^a   Czuczman, Natalie M ^a   Deeb, George ^a   Gibbs, John ^a   Skitzki, Joseph J ^a   Patil, Ritesh ^a   Czuczman, Myron S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

B cell lymphoma; bortezomib; MLN2238; proteasome inhibition; rituximab resistance; ubiquitin proteasome system

Indexed keywords

BORTEZOMIB; CASPASE; DOXORUBICIN; GEMCITABINE; IXAZOMIB; PACLITAXEL; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER MODEL; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; DRUG POTENCY; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; BORON COMPOUNDS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GLYCINE; HUMANS; PROTEASOME INHIBITORS; TIME FACTORS;

EID: 84885371629     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000008     Document Type: Article

References (33)

1. Ciechanover A. The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J 1998; 17:7151-7160.
2. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426:895-899.
3. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004; 4:349-360.
4. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000.
5. Mullard A. Next-generation proteasome blockers promise safer cancer therapy. Nat Med 2012; 18:7.
6. Cramer P, Hallek M. Hematological cancer in 2011: New therapeutic targets and treatment strategies. Nat Rev Clin Oncol 2012; 9:72-74.
7. Cvek B, Dvorak Z. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Curr Pharm De s 2011; 17:1483-1499.
8. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets 2011; 11:239-253.
9. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature. Blood 2008; 112:1593-1599.
10. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: A review of recent studies. Leuk Lymphoma 2010; 51:1178-1187.
11. Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011; 17:7313-7323.
12. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70:1970-1980.
13. Assouline S, Chang J, Rifkin R, Hui AM, Berg D, Gupta N, et al. MLN9708, a novel, investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma: Results of a phase dose-escalation study. ASH Annual Meeting Abstracts; December 2011; San Diego, CA, USA; 118: 2672.
14. Berdeja JG, Richardson PG, Lonial S, Niesvizky R, Hui AM, Berg D, et al. Phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and De xamethasone in patients with previously untreated multiple myeloma (MM). ASH Annual Meeting Abstracts; December 2011; San Diego, CA, USA; 118: 479.
15. Gupta N, Saleh M, Venkatakrishnan K. Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: Population pharmacokinetic (PK) analysis of pooled data from phase-1 studies. ASH Annual Meeting Abstracts; December 2011; San Diego, CA, USA; 118: 1433.
16. Kumar S, Bensinger WI, Reeder CB, Zimmerman TM, Berenson JR, Berg D, et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: Results from a phase dose-escalation study. ASH Annual Meeting Abstracts 2011; December 2011; San Diego, CA, USA; 118: 816.
17. Richardson PG, Baz R, Wang L, Jakubowiak AJ, Berg D, Liu GH, et al. Investigational agent MLN9708, an oral proteasome inhibitor, in patients (PTS) with relapsed and/or refractory multiple myeloma (MM): Results from the expansion cohorts of a phase dose-escalation study. ASH Annual Meeting Abstracts ; December 2011; San Diego, CA, USA; 118: 301.
18. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008; 14:1550-1560.
19. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008; 14:1561-1570.
20. Olejniczak SH, Blickwedehl J, Belicha-Villanueva A, Bangia N, RiazW, Mavis C, et al. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus-sensitive B-NHL cells. Blood 2010; 116:5605-5614.
21. Canfield SE, Zhu K, Williams SA, McConkey DJ. Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 2006; 5:2043-2050.
22. De nlinger CE, Rundall BK, Keller MD, Jones DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004; 78:1207-1214, discussion 1207-1214.
23. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-coral study. J Clin Oncol 2011; 29:4079-4087.
24. Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: An update of the CORAL study. Ann Oncol 2006; 17 (Suppl 4):iv31-iv32.
25. Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: Preclinical mechanistic studies. Ann Oncol 2010; 21:1756-1764.
26. Wright JJ. Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy. Clin Cancer Res 2010; 16:4094-4104.
27. Coiffier B. Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma' Nat Clin Pract Oncol 2005; 2:388-389.
28. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667-675.
29. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23:676-684.
30. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011; 17:5311-5321.
31. Broyl A, Jongen JL, Sonneveld P. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma. Semin Hematol 2012; 49:249-257.
32. Lonial S, Baz RC,Wang M, Talpaz M, Liu GH, Berg D, et al. Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM) [abstract]. J Clin Oncol 2012; 30:8017.
33. Kumar S, Bensinger W, Reeder C, Reeder CB, Berenson JR, Berg D, et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study [abstract]. J Clin Oncol 2012; 30:8034.